13F Pro Quality Score

27.2/100

Rank #2,474 of 2,879 stocks

View Materials peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

95.1/100

Profitability

1.3/100

Balance Sheet

5.2/100

Earnings Quality

30.0/100

Free Cash Flow

1.9/100

Institutional Flow

98.5/100

Revenue Scale

2.0/100

Dilution Risk

1.8/100

CBUS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cibus, Inc. (CBUS), a Materials sector company. 13F Pro's AI-powered ranking engine scores CBUS at 27.2/100 on a 32-signal composite quality model, placing it at rank #2,474 of 2,879 stocks — the bottom half of the AI-ranked universe. CBUS scores in the top quartile across institutional flow (98.5), revenue growth (95.1). Areas of concern include profitability (1.3) and free cash flow (1.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cibus, Inc. reports quarterly revenue of $1.7M, net income of $-21.2M, free cash flow of $-11.6M. Top institutional holders of CBUS by reported 13-F value include FMR, VANGUARD CAPITAL MANAGEMENT, DAVIDSON KEMPNER CAPITAL MANAGEMENT, based on the most recent SEC filings. CBUS trades on the Nasdaq exchange and files with the SEC under CIK 1705843. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CBUS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cibus, Inc. directly from SEC EDGAR. Cibus, Inc.'s 13F Pro composite quality score has ranged between 5 and 27 since 2024, currently 27.2 — an improving long-term trajectory across 18 quarterly and live scoring snapshots.

Fun facts about Cibus, Inc.

Quirks, history, and lore behind CBUS — the kind of stuff that makes a stock memorable.

  • 1
    The Basics
    A U.S. agricultural biotechnology company · listed on Nasdaq · headquartered in San Diego, California · focused on improving crop traits.
  • 2
    The Numbers
    A small-cap company with revenue in the low tens of millions — this is early-stage biotech territory, where the science spending runs well ahead of the sales.
  • 3
    The History
    Founded in the 2010s, the company was built around a proprietary platform for making precise edits to plant DNA without introducing foreign genes — a distinction that matters a lot to regulators.
  • 4
    The Secret
    Its core technology uses gene editing rather than traditional GMO methods, allowing it to develop crops that may sidestep the toughest regulatory hurdles faced by conventional biotech seed companies.
  • 5
    The Lore
    The company's name is a nod to the Latin word for food, and its pipeline targets traits like drought tolerance and yield improvement in major commodity crops — the kind of thing that could matter enormously as the climate shifts.
  • 6
    The Giveaway
    Ticker CBUS, Latin roots meaning "food," and a non-transgenic crop editing platform — this San Diego ag-biotech firm is quietly trying to feed a hotter, drier world one edited seed at a time.
▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.7M

Net Income

Q1 2026

$-21.2M

Free Cash Flow

Q1 2026

$-11.6M

ROIC

Q1 2026

-34.1%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1057.3% YoY
$1.8MFY 2023
FY19 $7.3MFY21 $26.0MFY22 $157.0KFY23 $1.8M

Net Income

-1484.4% YoY
$-267.6MFY 2023
FY19 $-39.6MFY21 $-29.2MFY22 $-16.9MFY23 $-267.6M

Operating Income

-1325.5% YoY
$-318.9MFY 2023
FY19 $-39.7MFY21 $-29.3MFY22 $-22.4MFY23 $-318.9M

EPS (Diluted)

-41.3% YoY
$-25.95FY 2023
FY19 FY21 $-0.78FY22 $-18.36FY23 $-25.95

Total Assets

+2328.1% YoY
$544.4MFY 2023
FY19 $88.1MFY21 $37.2MFY22 $22.4MFY23 $544.4M

Total Debt

$2.2MFY 2023
FY19 FY21 $0.00FY22 $0.00FY23 $2.2M

Op. Cash Flow

-138.6% YoY
$-46.2MFY 2023
FY19 $-32.0MFY21 $-18.8MFY22 $-19.4MFY23 $-46.2M

Get alerted when CBUS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cibus, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)
XBRL financial facts (revenue, EPS, margins)
Insider transactions (Form 4)
Institutional 13F holdings
Quality rankings (32 signals)
AI analyst debates & daily meetings
Historical financial trends
Peer comparison & sector analysis

Put CBUS on your watchlist

Track score changes the day Cibus, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Is CBUS a good stock to buy?

13F Pro's AI-powered analysis of Cibus, Inc. (CBUS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Materials sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CBUS are available on the CBUS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CBUS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CBUS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cibus, Inc.'s investment landscape.